GALAPAGOS NV (GXE.DE) Fundamental Analysis & Valuation

FRA:GXE • BE0003818359

Current stock price

27.72 EUR
-0.34 (-1.21%)
Last:

This GXE.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

5

1. GXE.DE Profitability Analysis

1.1 Basic Checks

  • In the past year GXE was profitable.
  • GXE had a negative operating cash flow in the past year.
  • In multiple years GXE reported negative net income over the last 5 years.
  • In the past 5 years GXE always reported negative operating cash flow.
GXE.DE Yearly Net Income VS EBIT VS OCF VS FCFGXE.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B

1.2 Ratios

  • Looking at the Return On Assets, with a value of 9.42%, GXE belongs to the top of the industry, outperforming 86.42% of the companies in the same industry.
  • GXE has a Return On Equity of 9.92%. This is amongst the best in the industry. GXE outperforms 81.48% of its industry peers.
  • With an excellent Return On Invested Capital value of 11.32%, GXE belongs to the best of the industry, outperforming 88.89% of the companies in the same industry.
Industry RankSector Rank
ROA 9.42%
ROE 9.92%
ROIC 11.32%
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
GXE.DE Yearly ROA, ROE, ROICGXE.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5 -5 -10

1.3 Margins

  • GXE has a better Profit Margin (28.85%) than 85.19% of its industry peers.
  • GXE has a Operating Margin of 47.04%. This is amongst the best in the industry. GXE outperforms 95.06% of its industry peers.
  • GXE has a Gross Margin of 97.33%. This is amongst the best in the industry. GXE outperforms 92.59% of its industry peers.
  • In the last couple of years the Gross Margin of GXE has declined.
Industry RankSector Rank
OM 47.04%
PM (TTM) 28.85%
GM 97.33%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
GXE.DE Yearly Profit, Operating, Gross MarginsGXE.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 50 -50 100 150

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

7

2. GXE.DE Health Analysis

2.1 Basic Checks

  • The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so GXE is still creating some value.
  • There is no outstanding debt for GXE. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
GXE.DE Yearly Shares OutstandingGXE.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M
GXE.DE Yearly Total Debt VS Total AssetsGXE.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2B 4B 6B

2.2 Solvency

  • An Altman-Z score of 8.37 indicates that GXE is not in any danger for bankruptcy at the moment.
  • GXE has a Altman-Z score of 8.37. This is amongst the best in the industry. GXE outperforms 85.19% of its industry peers.
  • GXE has a Debt/Equity ratio of 0.00. This is a healthy value indicating a solid balance between debt and equity.
  • GXE has a Debt to Equity ratio of 0.00. This is amongst the best in the industry. GXE outperforms 93.83% of its industry peers.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 8.37
ROIC/WACC1.43
WACC7.93%
GXE.DE Yearly LT Debt VS Equity VS FCFGXE.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B

2.3 Liquidity

  • GXE has a Current Ratio of 20.15. This indicates that GXE is financially healthy and has no problem in meeting its short term obligations.
  • With an excellent Current ratio value of 20.15, GXE belongs to the best of the industry, outperforming 97.53% of the companies in the same industry.
  • GXE has a Quick Ratio of 20.00. This indicates that GXE is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of GXE (20.00) is better than 97.53% of its industry peers.
Industry RankSector Rank
Current Ratio 20.15
Quick Ratio 20
GXE.DE Yearly Current Assets VS Current LiabilitesGXE.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 1B 2B 3B 4B 5B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

4

3. GXE.DE Growth Analysis

3.1 Past

  • The Earnings Per Share has grown by an impressive 334.82% over the past year.
  • GXE shows a strong growth in Revenue. In the last year, the Revenue has grown by 280.53%.
  • GXE shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 15.97% yearly.
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.16%

3.2 Future

  • Based on estimates for the next years, GXE will show a very negative growth in Earnings Per Share. The EPS will decrease by -25.26% on average per year.
  • GXE is expected to show a very negative growth in Revenue. In the coming years, the Revenue will decrease by -30.71% yearly.
EPS Next Y-150.44%
EPS Next 2Y-64.81%
EPS Next 3Y-30.23%
EPS Next 5Y-25.26%
Revenue Next Year-0.05%
Revenue Next 2Y-2.62%
Revenue Next 3Y-0.5%
Revenue Next 5Y-30.71%

3.3 Evolution

  • When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is decreasing.
GXE.DE Yearly Revenue VS EstimatesGXE.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2017 2019 2021 2023 2025 2027 2029 2031 2033 200M 400M 600M 800M 1B
GXE.DE Yearly EPS VS EstimatesGXE.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 0 2 -2 4 -4

More info and screens

Find the best growth stocksShow best growing peers

2

4. GXE.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • Based on the Price/Earnings ratio of 5.69, the valuation of GXE can be described as very cheap.
  • Based on the Price/Earnings ratio, GXE is valued cheaply inside the industry as 95.06% of the companies are valued more expensively.
  • GXE is valuated cheaply when we compare the Price/Earnings ratio to 25.23, which is the current average of the S&P500 Index.
  • The Forward Price/Earnings Ratio is negative for GXE. No positive earnings are expected for the next year.
Industry RankSector Rank
PE 5.69
Fwd PE N/A
GXE.DE Price Earnings VS Forward Price EarningsGXE.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
GXE.DE Per share dataGXE.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 10 20 30 40

4.3 Compensation for Growth

  • GXE's earnings are expected to decrease with -30.23% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-64.81%
EPS Next 3Y-30.23%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. GXE.DE Dividend Analysis

5.1 Amount

  • GXE does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

GXE.DE Fundamentals: All Metrics, Ratios and Statistics

GALAPAGOS NV

FRA:GXE (3/20/2026, 7:00:00 PM)

27.72

-0.34 (-1.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-24
Earnings (Next)N/A
Inst Owners25.24%
Inst Owner ChangeN/A
Ins Owners0%
Ins Owner ChangeN/A
Market Cap1.83B
Revenue(TTM)1.11B
Net Income(TTM)320.88M
Analysts52.22
Price Target31.35 (13.1%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr YearsN/A
Div Non Decr YearsN/A
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)-9817.73%
Min EPS beat(2)-19965.4%
Max EPS beat(2)329.9%
EPS beat(4)1
Avg EPS beat(4)-5598.11%
Min EPS beat(4)-19965.4%
Max EPS beat(4)329.9%
EPS beat(8)4
Avg EPS beat(8)-2634.25%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)1
Avg Revenue beat(2)487.53%
Min Revenue beat(2)-2.86%
Max Revenue beat(2)977.92%
Revenue beat(4)2
Avg Revenue beat(4)242.29%
Min Revenue beat(4)-10.27%
Max Revenue beat(4)977.92%
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0.84%
PT rev (3m)2.01%
EPS NQ rev (1m)0%
EPS NQ rev (3m)0%
EPS NY rev (1m)-36.8%
EPS NY rev (3m)-34.29%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)0%
Revenue NY rev (1m)-0.5%
Revenue NY rev (3m)-0.5%
Valuation
Industry RankSector Rank
PE 5.69
Fwd PE N/A
P/S 1.64
P/FCF N/A
P/OCF N/A
P/B 0.56
P/tB 0.56
EV/EBITDA N/A
EPS(TTM)4.87
EY17.57%
EPS(NY)-2.46
Fwd EYN/A
FCF(TTM)-4.12
FCFYN/A
OCF(TTM)-3.91
OCFYN/A
SpS16.88
BVpS49.1
TBVpS49.09
PEG (NY)N/A
PEG (5Y)N/A
Graham Number73.35
Profitability
Industry RankSector Rank
ROA 9.42%
ROE 9.92%
ROCE 16.08%
ROIC 11.32%
ROICexc 144.09%
ROICexgc 144.57%
OM 47.04%
PM (TTM) 28.85%
GM 97.33%
FCFM N/A
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y-20.64%
GM growth 5YN/A
F-Score6
Asset Turnover0.33
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales 1.25%
Interest Coverage 1127.48
Cash Conversion N/A
Profit Quality N/A
Current Ratio 20.15
Quick Ratio 20
Altman-Z 8.37
F-Score6
WACC7.93%
ROIC/WACC1.43
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)13.02%
Cap/Sales(5y)12.63%
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)334.82%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%3023.68%
EPS Next Y-150.44%
EPS Next 2Y-64.81%
EPS Next 3Y-30.23%
EPS Next 5Y-25.26%
Revenue 1Y (TTM)280.53%
Revenue growth 3Y58.87%
Revenue growth 5Y15.97%
Sales Q2Q%1093.16%
Revenue Next Year-0.05%
Revenue Next 2Y-2.62%
Revenue Next 3Y-0.5%
Revenue Next 5Y-30.71%
EBIT growth 1Y377.81%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year27.8%
EBIT Next 3Y20.58%
EBIT Next 5Y15.02%
FCF growth 1Y32.53%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.55%
OCF growth 3YN/A
OCF growth 5YN/A

GALAPAGOS NV / GXE.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of GALAPAGOS NV (GXE.DE) stock?

ChartMill assigns a fundamental rating of 5 / 10 to GXE.DE.


What is the valuation status of GALAPAGOS NV (GXE.DE) stock?

ChartMill assigns a valuation rating of 2 / 10 to GALAPAGOS NV (GXE.DE). This can be considered as Overvalued.


Can you provide the profitability details for GALAPAGOS NV?

GALAPAGOS NV (GXE.DE) has a profitability rating of 5 / 10.


What is the valuation of GALAPAGOS NV based on its PE and PB ratios?

The Price/Earnings (PE) ratio for GALAPAGOS NV (GXE.DE) is 5.69 and the Price/Book (PB) ratio is 0.56.


Can you provide the expected EPS growth for GXE stock?

The Earnings per Share (EPS) of GALAPAGOS NV (GXE.DE) is expected to decline by -150.44% in the next year.